FMOD and prostate cancer: To conclude, by using the Gleason score information supplemented with the expression of FMOD and PTPN2 genes, a stratification of prostate cancer patients into several prognostic subgroups with significantly different hazard ratios (low, medium, and high risk of progression) was achieved.